STOCKHOLM, March 7, 2024 /PRNewswire/ -- BioArctic AB's
(publ) (Nasdaq: BIOA B) (Stockholm: BIOA B) partner Eisai today
published a presentation including a simulation[1] of
potential future sales for Leqembi, the world's first fully
approved disease-modifying treatment for Alzheimer's disease.
According to Eisai's simulation, Leqembi sales will reach
JPY 290 billion for their financial
year (FY) 2026, which ends in March
2027 and JPY 1.6 trillion in
FY2032.
Eisai's presentation can be found on
https://www.eisai.com/ir/library/presentations/index.html.
This information is information that BioArctic AB (publ) is
obliged to disclose pursuant to the EU Market Abuse Regulation. The
information was released for public disclosure, through the agency
of the contact persons below, on March 7,
2023, at 06:30 a.m.
CET.
For further information, please contact:
Oskar Bosson, VP Communications and
IR
E-mail: oskar.bosson@bioarctic.com
Phone: +46 70 410 71 80
Jiang Millington, Director Corporate
Communication and Social Media
E-mail: jiang.millington@bioarctic.com
Phone: +46 79 33 99 166
About lecanemab (generic name, U.S., Japan and China brand name: Leqembi®)
Lecanemab (Leqembi) is the result of a strategic research alliance
between BioArctic and Eisai. It is a humanized immunoglobulin gamma
1 (IgG1) monoclonal antibody directed against aggregated soluble
(protofibril) and insoluble forms of amyloid-beta (Aβ). Lecanemab
is approved in the U.S., Japan and
China. In the U.S., Japan and China, the indications are as
follows.
- U.S.: For the treatment of Alzheimer's disease (AD). It should
be initiated in patients with mild cognitive impairment or mild
dementia stage of disease. Please see full U.S. Prescribing
Information.
- Japan: For slowing progression
of mild cognitive impairment (MCI) and mild dementia due to
AD.
- China: For the treatment of
MCI due to AD and mild AD dementia.
About the collaboration between BioArctic and Eisai
Since 2005, BioArctic has a long-term collaboration with Eisai
regarding the development and commercialization of drugs for the
treatment of Alzheimer's disease. The most important agreements are
the Development and Commercialization Agreement for the lecanemab
antibody, which was signed 2007, and the Development and
Commercialization agreement for the antibody lecanemab back-up for
Alzheimer's disease, which was signed 2015. In 2014, Eisai and
Biogen entered into a joint development and commercialization
agreement for lecanemab. Eisai is responsible for the clinical
development, application for market approval and commercialization
of the products for Alzheimer's disease. BioArctic has the right to
commercialize lecanemab in the Nordic region under certain
conditions and is currently preparing for commercialization in the
Nordics together with Eisai. BioArctic has no development costs for
lecanemab in Alzheimer's disease and is entitled to payments in
connection with regulatory approvals, and sales milestones as well
as royalties on global sales.
About BioArctic AB
BioArctic AB (publ) is a Swedish research-based biopharma company
focusing on innovative treatments that can delay or stop the
progression of neurodegenerative diseases. The company invented
Leqembi® (lecanemab) – the world's first drug proven to slow the
progression of the disease and reduce cognitive impairment in early
Alzheimer's disease. Leqembi has been developed together with
BioArctic's partner Eisai, who are responsible for regulatory
interactions and commercialization globally. In addition to
Leqembi, BioArctic has a broad research portfolio with antibodies
against Parkinson's disease and ALS as well as additional projects
against Alzheimer's disease. Several of the projects utilize the
company's proprietary BrainTransporter™ technology, which has the
potential to actively transport antibodies across the blood-brain
barrier to enhance the efficacy of the treatment. BioArctic's B
share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For further
information, please visit www.bioarctic.se.
[1] Simulation not to be seen as guidance
according to Eisai
The following files are available for download:
https://mb.cision.com/Main/9978/3942094/2653275.pdf
|
BioArctic’s partner
Eisai presents updated sales simulation for Leqembi® at its annual
press conference
|
View original
content:https://www.prnewswire.co.uk/news-releases/bioarctics-partner-eisai-presents-updated-sales-simulation-for-leqembi-at-its-annual-press-conference-302082469.html